Zevra Therapeutics, Inc.
ZVRA
$11.05
$0.252.32%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 124.22M | 83.23M | 35.33M | 2.64M | -91.99M |
| Total Depreciation and Amortization | 2.77M | 4.05M | 5.34M | 6.57M | 6.48M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -104.14M | -62.37M | -42.20M | -35.69M | 37.68M |
| Change in Net Operating Assets | -10.08M | -26.51M | -21.83M | -19.74M | -13.89M |
| Cash from Operations | 12.77M | -1.60M | -23.36M | -46.21M | -61.72M |
| Capital Expenditure | -771.00K | -835.00K | -866.00K | -312.00K | -99.00K |
| Sale of Property, Plant, and Equipment | 44.43M | 448.00K | 589.00K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 43.55M | 18.51M | 12.71M | -14.04M | -26.31M |
| Cash from Investing | 87.20M | 18.13M | 12.43M | -14.35M | -26.41M |
| Total Debt Issued | -- | -- | 0.00 | 0.00 | 60.07M |
| Total Debt Repaid | -60.09M | -372.00K | -372.00K | -372.00K | -43.50M |
| Issuance of Common Stock | 20.38M | 12.44M | 10.69M | 68.92M | 68.02M |
| Repurchase of Common Stock | -2.64M | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | 0.00 | -2.09M |
| Cash from Financing | -42.35M | 12.06M | 10.31M | 68.55M | 82.50M |
| Foreign Exchange rate Adjustments | 633.00K | 28.00K | 1.02M | 466.00K | 127.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 58.26M | 28.62M | 400.00K | 8.45M | -5.51M |